![Insulet gives go-ahead for more TV ads, prepping for Omnipod 5 launch later this year | Fierce Pharma Insulet gives go-ahead for more TV ads, prepping for Omnipod 5 launch later this year | Fierce Pharma](https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1615222152/Insulet%20Omnipod%20Working.jpg/Insulet%20Omnipod%20Working.jpg?VersionId=Ef4aXEMvajcff.VC25u07wg3BURqKasG)
Insulet gives go-ahead for more TV ads, prepping for Omnipod 5 launch later this year | Fierce Pharma
![With new Medtronic pact, Novo Nordisk's smart insulin pen to link with all major CGMs | Fierce Biotech With new Medtronic pact, Novo Nordisk's smart insulin pen to link with all major CGMs | Fierce Biotech](https://qtxasset.com/quartz/qcloud5/media/image/fiercebiotech/1568641565/novonordiskflagfly.jpg/novonordiskflagfly.jpg?VersionId=Vi2ZYkRq.VvtngwFRgIdocXduVBg7jnq)
With new Medtronic pact, Novo Nordisk's smart insulin pen to link with all major CGMs | Fierce Biotech
![Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial](https://diatribe.org/sites/default/files/Victoza_0.jpg)
Combination of Novo Nordisk's Insulin degludec and Victoza Provides Synergistic Benefits in Late-Stage Trial
![Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps](https://pharmashots.com/public/images/20211115235833_ogImage_43.jpg)
Novo Nordisk's Fiasp (insulin aspart injection) Receives the FDA's Approval for use in Insulin Infusion Pumps
![Patient-reported outcomes for 2,335 adults with type 2 diabetes using the Omnipod® Insulin Management System show glycaemic improvement over the first 90 days of use - Media Centre | EASD Patient-reported outcomes for 2,335 adults with type 2 diabetes using the Omnipod® Insulin Management System show glycaemic improvement over the first 90 days of use - Media Centre | EASD](https://d2t0unnjxes6lt.cloudfront.net/data/easd/data/talks/1059_718774_2/Slide1.jpg)
Patient-reported outcomes for 2,335 adults with type 2 diabetes using the Omnipod® Insulin Management System show glycaemic improvement over the first 90 days of use - Media Centre | EASD
![Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes | Diabetes Technology & Therapeutics Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes | Diabetes Technology & Therapeutics](https://www.liebertpub.com/cms/10.1089/dia.2019.0356/asset/images/medium/dia.2019.0356_figure1.jpg)
Safety and Effectiveness of an Investigational Insulin Delivery Device Providing Basal/Bolus Therapy with Rapid-Acting or Regular Human Insulin in Adults with Type 2 Diabetes | Diabetes Technology & Therapeutics
![Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - ScienceDirect Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0085253819303229-fx1.jpg)
Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis - ScienceDirect
![Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial - The Lancet Diabetes & Endocrinology Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial - The Lancet Diabetes & Endocrinology](https://www.thelancet.com/cms/attachment/556a1a34-3dcf-48fc-b48a-790cfc76365d/gr1.gif)